These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15161793)

  • 1. Neuroendocrine tumor markers and enterochromaffin-like cell hyper/dysplasia in type 1 diabetes.
    De Block CE; Colpin G; Thielemans K; Coopmans W; Bogers JJ; Pelckmans PA; Van Marck EA; Van Hoof V; Martin M; De Leeuw IH; Bouillon R; Van Gaal LF
    Diabetes Care; 2004 Jun; 27(6):1387-93. PubMed ID: 15161793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy.
    Sanduleanu S; De Bruïne A; Stridsberg M; Jonkers D; Biemond I; Hameeteman W; Lundqvist G; Stockbrügger RW
    Eur J Clin Invest; 2001 Sep; 31(9):802-11. PubMed ID: 11589723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoimmune gastropathy in type 1 diabetic patients with parietal cell antibodies: histological and clinical findings.
    De Block CE; De Leeuw IH; Bogers JJ; Pelckmans PA; Ieven MM; Van Marck EA; Van Acker KL; Van Gaal LF
    Diabetes Care; 2003 Jan; 26(1):82-8. PubMed ID: 12502662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors.
    Bajetta E; Ferrari L; Martinetti A; Celio L; Procopio G; Artale S; Zilembo N; Di Bartolomeo M; Seregni E; Bombardieri E
    Cancer; 1999 Sep; 86(5):858-65. PubMed ID: 10463986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
    Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids.
    Peracchi M; Gebbia C; Basilisco G; Quatrini M; Tarantino C; Vescarelli C; Massironi S; Conte D
    Eur J Endocrinol; 2005 Mar; 152(3):443-8. PubMed ID: 15757862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypergastrinemia as a cause of chromogranin a increase in blood in patients suspected to have neuroendocrine tumor.
    Kleveland O; Syversen U; Slørdahl K; Waldum HL
    Digestion; 2001; 64(2):71-4. PubMed ID: 11684818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study.
    Sanduleanu S; Stridsberg M; Jonkers D; Hameeteman W; Biemond I; Lundqvist G; Lamers C; Stockbrügger RW
    Aliment Pharmacol Ther; 1999 Feb; 13(2):145-53. PubMed ID: 10102943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.
    Nisman B; Heching N; Biran H; Barak V; Peretz T
    Tumour Biol; 2006; 27(1):8-16. PubMed ID: 16340245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
    Baudin E; Gigliotti A; Ducreux M; Ropers J; Comoy E; Sabourin JC; Bidart JM; Cailleux AF; Bonacci R; Ruffié P; Schlumberger M
    Br J Cancer; 1998 Oct; 78(8):1102-7. PubMed ID: 9792158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromogranin A (CGA) and the enterochromaffin-like (ECL) cell.
    Waldum HL; Syversen U
    Adv Exp Med Biol; 2000; 482():361-7. PubMed ID: 11192596
    [No Abstract]   [Full Text] [Related]  

  • 12. Serum chromogranin A level continuously rises with the progression of type 1 diabetes, and indicates the presence of both enterochromaffin-like cell hyperplasia and autoimmune gastritis.
    Herold Z; Herold M; Nagy P; Patocs A; Doleschall M; Somogyi A
    J Diabetes Investig; 2020 Jul; 11(4):865-873. PubMed ID: 31883432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroendocrine serum tumour markers in hormone-resistant prostate cancer.
    Hvamstad T; Jordal A; Hekmat N; Paus E; Fosså SD
    Eur Urol; 2003 Aug; 44(2):215-21. PubMed ID: 12875941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The gastric mucosa 25 years after proximal gastric vagotomy.
    Sagatun L; Jianu CS; Fossmark R; Mårvik R; Nordrum IS; Waldum HL
    Scand J Gastroenterol; 2014 Oct; 49(10):1173-80. PubMed ID: 25157752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of silent gastric carcinoid in a type 1 diabetic patient with primer hypothyreosis].
    Somogyi A; Ruzicska E; Varga T; Rácz K; Nagy G
    Orv Hetil; 2007 Sep; 148(35):1667-71. PubMed ID: 17720674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
    Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
    Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromogranin Serves as Novel Biomarker of Endocrine and Gastric Autoimmunity.
    Ebert A; König J; Frommer L; Schuppan D; Kahaly GJ
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32436949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia.
    Jianu CS; Fossmark R; Syversen U; Hauso Ø; Waldum HL
    Tumour Biol; 2010 Oct; 31(5):373-80. PubMed ID: 20480408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are patients with autoimmune thyroid disease and autoimmune gastritis at risk of gastric neuroendocrine neoplasms type 1?
    Alexandraki KI; Nikolaou A; Thomas D; Syriou V; Korkolopoulou P; Sougioultzis S; Kaltsas G
    Clin Endocrinol (Oxf); 2014 May; 80(5):685-90. PubMed ID: 24118101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
    Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
    Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.